Pharma

Your Article Summary

See Latest Articles

FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Roche, 09/02/09

Roche announced that the U.S. Food and Drug Administration has approved Valcyte for the prevention of cytomegalovirus disease in pediatric kidney and heart transplant patients at high risk of developing CMV disease. The FDA also approved a new pediatric oral solution formulation for Valcyte, which will allow easier administration to pediatric patients 4 months to 16 years of age.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Zoster vaccination: A new opportunity for adult immunization
Canadian Journal of Infectious Diseases, 12/15/09

FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

 See all of Drug/Product Approvals